Subtopic Deep Dive
Epidemiology of Ocular Inflammatory Diseases
Research Guide
What is Epidemiology of Ocular Inflammatory Diseases?
Epidemiology of ocular inflammatory diseases studies prevalence, incidence, geographic variations, and risk factors of uveitis and related conditions like those associated with juvenile idiopathic arthritis.
Key studies report uveitis prevalence at 121 per 100,000 adults and 29 per 100,000 children in the US (Thorne et al., 2016, 249 citations). Systematic reviews of 2619 patients show uveitis links to systemic diseases and infections (Barisani-Asenbauer et al., 2012, 243 citations). Cohort analyses highlight visual loss in two-thirds of patients, with 22% experiencing legal blindness (Durrani, 2004, 506 citations).
Why It Matters
Epidemiological data from Thorne et al. (2016) inform US public health screening for noninfectious uveitis, reducing blindness risk in at-risk populations. Angeles-Han et al. (2013, 133 citations) identify JIA-uveitis risk markers in CARRA registry, guiding pediatric screening protocols. Barisani-Asenbauer et al. (2012) associations with systemic diseases shape global diagnostic registries, optimizing resource allocation in ophthalmology clinics.
Key Research Challenges
Heterogeneous Diagnostic Criteria
Uveitis classification varies across studies, complicating prevalence comparisons (Barisani-Asenbauer et al., 2012). Registry data like CARRA shows inconsistent uveitis reporting in JIA cohorts (Angeles-Han et al., 2013). Standardization efforts lag despite consensus initiatives (Constantin et al., 2018).
Geographic Variation Gaps
US-focused claims data overestimate prevalence in underrepresented regions (Thorne et al., 2016). Global patterns from 2619-patient reviews reveal understudied infections in non-Western cohorts (Barisani-Asenbauer et al., 2012). Risk factor mapping requires multinational registries.
Long-term Outcome Tracking
Visual loss persists in two-thirds of uveitis patients over follow-up (Durrani, 2004). JIA-uveitis registries track incidence but lack lifelong blindness predictors (Angeles-Han et al., 2013). Prospective cohorts needed for incidence-risk modeling.
Essential Papers
Degree, duration, and causes of visual loss in uveitis
Omar M. Durrani · 2004 · British Journal of Ophthalmology · 506 citations
Prolonged visual loss occurred in two thirds of uveitis patients, with 70 (22%) patients meeting the criteria for legal blindness at some point in their follow up. Older patients with bilateral inf...
Prevalence of Noninfectious Uveitis in the United States
Jennifer E. Thorne, Eric B. Suhler, Martha Skup et al. · 2016 · JAMA Ophthalmology · 249 citations
The estimated prevalence of NIU was 121 cases per 100 000 for adults (95% CI, 117.5-124.3) and 29 per 100 000 for children (95% CI, 26.1-33.2). Prevalence was estimated using administrative claims ...
Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients
Talin Barisani‐Asenbauer, S. Maca, Lamiss Mejdoubi et al. · 2012 · Orphanet Journal of Rare Diseases · 243 citations
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
Tamás Constantin, Ivan Foeldvari, Jordi Antón et al. · 2018 · Annals of the Rheumatic Diseases · 196 citations
The SHARE initiative aims to identify best practices for treatment of patients suffering from JIA-associated uveitis. Within this remit, recommendations for the diagnosis and treatment of JIA-assoc...
Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network
Hélène Vallet, P. Sève, Lucie Biard et al. · 2016 · Arthritis & Rheumatology · 170 citations
Objective To analyze the factors associated with response to anti–tumor necrosis factor (anti‐TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients...
Autophagy regulates death of retinal pigment epithelium cells in age-related macular degeneration
Kai Kaarniranta, Paulina Tokarz, Ali Koskela et al. · 2016 · Cell Biology and Toxicology · 166 citations
Age-related macular degeneration (AMD) is an eye disease underlined by the degradation of retinal pigment epithelium (RPE) cells, photoreceptors, and choriocapillares, but the exact mechanism of ce...
Central Role of Oxidative Stress in Age-Related Macular Degeneration: Evidence from a Review of the Molecular Mechanisms and Animal Models
Samuel Abokyi, Chi Ho To, Tim T. Lam et al. · 2020 · Oxidative Medicine and Cellular Longevity · 163 citations
Age-related macular degeneration (AMD) is a common cause of visual impairment in the elderly. There are very limited therapeutic options for AMD with the predominant therapies targeting vascular en...
Reading Guide
Foundational Papers
Read Durrani (2004) first for uveitis visual loss baselines (506 citations), then Barisani-Asenbauer et al. (2012) for systemic associations in 2619 patients, and Angeles-Han et al. (2013) for JIA registry risks.
Recent Advances
Study Thorne et al. (2016) for US NIU prevalence (249 citations), Constantin et al. (2018) SHARE consensus for JIA-uveitis management, and Clarke et al. (2016) for pediatric updates.
Core Methods
Core methods: claims-based prevalence estimation (Thorne 2016), CARRA registry risk modeling (Angeles-Han 2013), systematic patient reviews (Barisani-Asenbauer 2012), and consensus guidelines (Constantin 2018).
How PapersFlow Helps You Research Epidemiology of Ocular Inflammatory Diseases
Discover & Search
Research Agent uses searchPapers('uveitis epidemiology JIA') to retrieve Thorne et al. (2016), then citationGraph reveals 249 citing papers on prevalence trends, and findSimilarPapers uncovers Angeles-Han et al. (2013) CARRA registry parallels.
Analyze & Verify
Analysis Agent applies readPaperContent on Durrani (2004) to extract 22% blindness rates, verifies cohort biases via verifyResponse (CoVe), and runPythonAnalysis on prevalence CIs (Thorne et al., 2016) with GRADE grading for moderate evidence quality in claims data.
Synthesize & Write
Synthesis Agent detects gaps in geographic JIA-uveitis data via gap detection on Barisani-Asenbauer et al. (2012), flags contradictions in infection associations, then Writing Agent uses latexEditText for cohort summaries, latexSyncCitations for 10-paper review, and latexCompile for polished manuscript with exportMermaid for incidence flowcharts.
Use Cases
"Analyze prevalence differences in JIA-uveitis across registries using Python stats"
Research Agent → searchPapers('JIA uveitis registry') → Analysis Agent → runPythonAnalysis(pandas on CARRA data from Angeles-Han 2013 + Thorne 2016 CIs) → researcher gets matplotlib plots of incidence ratios and p-values.
"Draft LaTeX section on uveitis visual loss epidemiology"
Synthesis Agent → gap detection(Durrani 2004 + Constantin 2018) → Writing Agent → latexEditText('visual loss cohorts') → latexSyncCitations(5 papers) → latexCompile → researcher gets PDF section with formatted tables.
"Find code for uveitis risk factor modeling from papers"
Research Agent → paperExtractUrls(Angeles-Han 2013) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets R scripts for CARRA logistic regression on JIA risk markers.
Automated Workflows
Deep Research workflow runs systematic review: searchPapers('ocular inflammatory epidemiology', 50+ hits) → citationGraph(Thorne 2016 cluster) → structured report on prevalence gaps. DeepScan applies 7-step analysis with CoVe checkpoints on Durrani (2004) blindness data, verifying 506-citation impact. Theorizer generates JIA-uveitis risk hypotheses from Angeles-Han (2013) + Clarke (2016) synthesis.
Frequently Asked Questions
What is the definition of epidemiology in ocular inflammatory diseases?
It examines prevalence, incidence, geographic variations, and risk factors of uveitis and JIA-associated conditions using cohort studies and registries.
What are key methods in this subtopic?
Methods include administrative claims analysis (Thorne et al., 2016), systematic reviews of 2619 patients (Barisani-Asenbauer et al., 2012), and CARRA registry cohorts (Angeles-Han et al., 2013).
What are foundational papers?
Durrani (2004, 506 citations) quantifies visual loss in uveitis; Barisani-Asenbauer et al. (2012, 243 citations) links to systemic diseases; Angeles-Han et al. (2013, 133 citations) maps JIA-uveitis risks.
What open problems exist?
Challenges include standardizing diagnostics across regions, expanding non-US registries beyond Thorne (2016), and modeling long-term blindness from Durrani (2004) predictors.
Research Ocular Diseases and Behçet’s Syndrome with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Epidemiology of Ocular Inflammatory Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers